1. Home
  2. XSLL vs ACIU Comparison

XSLL vs ACIU Comparison

Compare XSLL & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XSLL

Xsolla SPAC 1 Class A Ordinary Shares

N/A

Current Price

$10.05

Market Cap

276.8M

Sector

Finance

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

SELL

Current Price

$1.98

Market Cap

229.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
XSLL
ACIU
Founded
2025
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.8M
229.7M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
XSLL
ACIU
Price
$10.05
$1.98
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.36
AVG Volume (30 Days)
39.4K
★ 216.7K
Earning Date
N/A
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$422.39
Revenue Next Year
N/A
$377.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.80
$2.00
52 Week High
$10.05
$3.90

Technical Indicators

Market Signals
Indicator
XSLL
ACIU
Relative Strength Index (RSI) 65.53 37.96
Support Level $9.99 N/A
Resistance Level N/A $2.49
Average True Range (ATR) 0.01 0.15
MACD 0.00 -0.01
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
XSLL
ACIU

About XSLL Xsolla SPAC 1 Class A Ordinary Shares

Xsolla SPAC 1 is a blank check company.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: